Novo Nordisk A/S ADR (NVO)

$135.62 0.00 (0.00%)

19:00 EDT NVO Stock Quote Delayed 30 Minutes

7 Biotech Stocks to Put on Your Breakthrough Radar

By Josh Enomoto, InvestorPlace Contributor May 27, 2024

For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let’s get some of…

3 Underappreciated Biotech Stocks to Buy Now: May 2024

7 Biotech Stocks That Could Breathe New Life Into Your Portfolio

Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 11,063

Day's Range -

52-Week Range $75.56 - $138.28

Dividend & Yield $1.77 (1.30%)

NVO Stock Predictions, Articles, and Novo Nordisk A/S ADR News

From InvestorPlace
From the Web

7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs

By Alex Sirois, InvestorPlace Contributor May 16, 2024

AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up.

Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade

By Rich Duprey, InvestorPlace Contributor May 16, 2024

The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.

Biotech Behemoths: 3 Giants Set to Dominate the Health Scene

By Joey Frenette, InvestorPlace Contributor May 14, 2024

The biotech behemoths stand out as compelling and exciting options for investors seeking steady long-term growth.

7 Stocks That Ordinary Investors Can’t Get Enough Of Right Now

By Josh Enomoto, InvestorPlace Contributor May 10, 2024

In an ecosystem where individuality is celebrated and groupthink is criticized, it may seem imprudent to target popular stocks among retail investors. However, putting minds…

Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare

By Josh Enomoto, InvestorPlace Contributor May 7, 2024

Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because…

3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030

By Omor Ibne Ehsan May 3, 2024

These under-the-radar stocks have the potential to reach a $1 trillion valuation by 2030 as they gain momentum in their respective industries.

NVO Stock Earnings: Novo Nordisk Beats EPS, Beats Revenue for Q1 2024

By InvestorPlace Earnings May 2, 2024

NVO stock results show that Novo Nordisk beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Profit from the Panic: 3 Stocks to Pounce on When They Become Steals

By Rich Duprey, InvestorPlace Contributor May 1, 2024

We love it when our favorite clothes go on sale, so when the market offers us a deal, these are the stocks to buy on dips.

3 of Europe’s ‘Magnificent 18’ Stocks That You Can Buy in the U.S.

By Will Ashworth, InvestorPlace Contributor Apr 30, 2024

The Magnificent Seven is so yesterday. The new trend is to invest in some of the top European stocks, dubbed the Magnificent 18.

3 Biotech Stocks With Skyrocketing Potential: April 2024

By Muslim Farooque, InvestorPlace Contributor Apr 24, 2024

These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time.

3 Biotech Stocks Set to Double by 2028

By Terel Miles, InvestorPlace Contributor Apr 20, 2024

These are three of the top biotech stocks set to double by 2028. Add them to your portfolio to maximize your potential gains.

3 Pharma Stocks That Are Money-Printing Machines in 2024

By Michael Que, InvestorPlace Contributor Apr 15, 2024

The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks.

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

By Louis Navellier and the InvestorPlace Research Staff Apr 12, 2024

We’re using the Portfolio Grader to find the best biotech stocks to buy in today’s market. Each of these stocks get top grades.

Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027

By Chris MacDonald, InvestorPlace Contributor Apr 12, 2024

For investors looking for a way to play weight-loss stocks in this current backdrop, here are three top options to consider right now.

All-Time High Flyers: 7 Stocks to Buy as the Market Peaks

By Joel Baglole, InvestorPlace Contributor Apr 11, 2024

These stocks to buy have enjoyed big rallies and the gains look likely to continue in coming months even if the market does peak.

3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild

By Shane Neagle, InvestorPlace Contributor Apr 10, 2024

Discover top obesity drug stocks set to soar as demand surges. Eli Lilly, Novo Nordisk, & Dexcom lead with revolutionary treatments

3 Underappreciated Healthcare Stocks to Buy Now: April 2024

By Terel Miles, InvestorPlace Contributor Apr 3, 2024

Novo Nordisk (NVO), United Therapeutics (UTHR) and Vertex Pharmaceuticals (VRTX) are three underappreciated healthcare stocks to buy in April.

Hedge Fund Favorites: 3 European Stocks Attracting Significant U.S. Investment

By Joel Baglole, InvestorPlace Contributor Apr 3, 2024

Investors looking for diversification should consider these European names that are increasingly popular among hedge fund managers.

Knocking on the Trillion-Dollar Door: 3 Stocks Ready to Shatter the Market Cap Milestone

By Joey Frenette, InvestorPlace Contributor Mar 28, 2024

The trillion-dollar market cap club could fill with some high-momentum large-caps that could give the Magnificent Seven a good run.

3 Healthcare Stocks to Buy From 3 of the Best Actively Managed Funds

By Will Ashworth, InvestorPlace Contributor Mar 28, 2024

Although the performance of these three healthcare stocks has been inconsistent in 2024, they remain undervalued.

Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030

From The Motley Fool Jun 2, 2024

These two drugmakers have a lot more in common than their market-beating potential.

Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run

From The Motley Fool Jun 2, 2024

Medicare just revised its guidelines to include coverage of Wegovy for patients with cardiovascular complications.

Novo Nordisk A/S ADR (NVO)

7 Biotech Stocks to Put on Your Breakthrough Radar

3 Underappreciated Biotech Stocks to Buy Now: May 2024

7 Biotech Stocks That Could Breathe New Life Into Your Portfolio

Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Novo Nordisk A/S ADR (NVO)

Top 5 Stocks for 2024

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

NVO Stock Predictions, Articles, and Novo Nordisk A/S ADR News

Subscriber Sign in